Articles related to CLINICAL TRIALS

Semaglutide treatment led to more frequent improvement and less frequent deterioration in NYHA functional class compared to placebo in patients with obesity-related HFpEF over 52 weeks.

Many modern oncology trials prioritize drug approval over patient welfare, often using inferior control arms that do not reflect the best available treatment.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.

Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.

The FDA has withdrawn approval for infigratinib in advanced cholangiocarcinoma following Helsinn Healthcare SA’s request, citing recruitment difficulties for a confirmatory trial.

The 2024 ASCO Annual Meeting reveals critical updates on lung and blood cancers, including promising phase 3 trial results and the innovative use of AI to reengage marginalized patients in cancer care.